Hepatitis C Complications

Hepatitis C drug is cost-effective for treatment-induced anemia

Published in Hepatitis Weekly, October 24th, 2005

A University of California at Los Angeles (UCLA)/VA study found that for hepatitis C patients who develop treatment-induced anemia due to a key medication, it is more cost-effective to take an additional drug to help prevent anemia, rather than reducing or stopping treatment altogether, which had been the standard approach.

The study may lead to a new treatment standard for the one-third of hepatitis C patients who develop treatment-induced anemia as a result of taking a key medication called ribarvirin. Over 4 million Americans are infected with hepatitis C. The research appeared in Clinical Gastroenterology and Hepatology.

Ribarvin, a common...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Hepatitis Weekly

Source: Hepatitis Weekly (2005-10-24)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry